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α-Vinylic amino acids: occurrence, asymmetric synthesis, and
biochemical mechanisms
David B. Berkowitz, Bradley D. Charette, Kannan R. Karukurichi, and Jill M. McFadden
Department of Chemistry, University of Nebraska–Lincoln, Lincoln, NE 68588-0304

Abstract — This report presents an overview of the family of naturally occurring “vinylic”
amino acids, namely those that feature a C–C double bond directly attached to the α-carbon,
along the side chain. Strategies that have been brought to bear on the stereocontrolled
synthesis of these olefinic amino acids are surveyed. The mechanistic diversity by which
such “vinylic triggers” can be actuated in a PLP (pyridoxal phosphate) enzyme active site is
then highlighted by discussion of vinylglycine (VG), its substituted congeners, particularly
AVG [4E-(2′-aminoethoxy)vinylglycine], and a naturally occurring VG-progenitor, SMM
[(S)-methylmethionine].
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1. Introduction
Enzymes that depend on the cofactor, pyridoxal phosphate
(PLP),1 generally serve to transform amino acids. In contrast
to the amino acid decarboxylases (e.g., L-DOPA or L-ornithine
decarboxylase) and the retroaldolases (e.g., serine hydroxymethyltransferase), most classes of PLP enzymes initiate their
chemistry by abstracting the α-proton of the substrate amino
acid. These include: (i) transaminases, such as γ-aminobutyrate (GABA) transaminase, that interconvert amino acids and
their corresponding α-keto acids; (ii) racemases, such as alanine racemase, a key bacterial cell wall biosynthetic enzyme;
(iii) β-eliminase or replacement enzymes, such as cystathionine β-synthase (CBS), a key human transsulfuration enzyme,
and (iv) γ-eliminase or replacement enzymes, such as cystathionine γ-lyase (CGL), the next enzyme in this pathway. For
the latter enzymatic class, a subsequent β-deprotonation is
also necessary. The eliminase or replacement enzymes, then
subsequently expel the leaving group attached to the β- or γcarbon, respectively, using the electron density imported into
the PLP π-system from the deprotonation step(s).
As can be seen in Figure 1, α-vinylic amino acids feature
a C–C double bond directly attached to the α-carbon atom.
If an α-proton is also present, one may regard these as vinylglycine congeners. For such amino acids, removal of the
α-proton has the effect of conjugating the otherwise isolated vinyl group with the extended π-system of the cofactor.
This can lead to a more reactive intermediate, as will be discussed later. At the outset, it suffices to note the correspondence between the initial step in the mechanism of many
PLP enzymes and the initial step in the unmasking of the vinyl group in this class of amino acids.

Figure 1. PLP enzymes that α-deprotonate and α-vinylic amino acid structure.

2. Natural occurrence
Perhaps, seeking to capitalize on the latent reactivity of the
double bond, in some cases, perhaps benefiting from the “conformational constraint” afforded by the sp2-alkene geometry,
in others, Nature has evolved a class of α-vinylic amino acids—the subject of this Report. Note that the discussion herein will be restricted to the class of vinylic amino acids bearing
unsaturation directly attached to the α-center, and also bearing an α-proton. Quaternary α-vinylic amino acids represent
both a structurally and functionally distinct amino acid class,
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as these do not possess an α-proton and, thus target a different
set of PLP enzymes (vide supra).2, 3, 4, 5, 6, & 7
2.1. Vinylglycine
Among the naturally occurring α-vinylic amino acids,
the simplest and probably most widely studied member of
the family is α-vinylglycine (VG) itself. The D-antipode is
known to be produced by the mushroom, Rhodophyllus nidorosus.8 On the other hand, the antipode, L-VG is generated
in a variety of PLP enzyme active sites. For example, L-VG
is observed as a mechanistic intermediate to α-ketobutyrate
in the reaction catalyzed by cystathionine γ-synthase,9 and in
the conversion of homoserine to threonine by threonine synthetase.10 L-VG is a substrate for sheep liver threonine deaminase,11 E. coli tryptophan synthetase,12 rat liver cystathionine γ-lyase and Salmonella typhimerium cystathionine
γ-synthetase.13 L-VG also reportedly undergoes deamination
and γ-addition by L-methionine γ-lyase.14 & 15 D-VG is a substrate (processed to α-ketobutyrate and NH3), but not inhibitor, of ACC deaminase, while L-VG is neither (Fig. 2).16

Figure 2. Naturally occurring vinylglycine antipodes.

Perhaps because of its small side chain, the parent member of
the family displays a rather broad spectrum of transaminase
inhibition. Thus, (dl)-VG inhibits aspartate aminotransferase,17 & 18 D-amino acid transaminase,13 and kynurenine aminotransferase,19 whereas the D-isomer has been specifically
shown to inhibit rat hepatic alanine aminotransferase.18
Interestingly, it appears that one can also tap into radical based
inactivation pathways with VG. Thus, the flavoenzyme L-amino acid oxidase is presumably inactivated by the L-antipode,
though, to the best of our knowledge, these studies have only
been performed on the racemate.20 In a complementary study,
Vederas and Zabriskie have shown that the tripeptide D-Phe-LPhe-D-VG inactivates peptide α-hydroxylating enzyme, an enzyme responsible for installing C-terminal carboxamide functionality.21 & 22 Interestingly, inversion of the stereocenter of
the terminal amino acid to L-VG yields a tripeptide that displays only reversible inhibition of the enzyme.
L-VG also irreversibly inactivates the nifS gene product, an
enzyme that releases S from L-cysteine for Fe–S cluster biosynthesis.23 Finally, the best characterization of the mode of
inactivation of a PLP enzyme by VG is for the enzyme ACC
(1-aminocyclopropane-1-carboxylate) synthase.24, 25, 26, 27, & 28
This is discussed in considerable detail in Section 4.
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2.2. β-Substituted
Three naturally occurring β-substituted vinylglycine analogues
are described in the literature (Fig. 3). L-3,4-Didehydrovaline
2 is a constituent of the 13-membered macrocycle phomopsin
A, isolated from Phomopsis leptostromifrmis.29 & 30 β-Methylene-L-norvaline 3 has been isolated from both Lactarius helvus31 and Philadelphus coronarius.32 Finally, β-methylene-Lnorleucine 4 is found in isolates from Amanita vaginata.33

Figure 4. γ-Substituted vinylic amino acids.
Figure 3. β-Substituted vinylglycines from natural sources.

2.3. γ-Substituted
As is shown in Figure 4, there is a notable spectrum of γ-substituted vinylglycine-based natural products. Several of these
have an interesting enol ether substructure that appears to influence the mechanism (vide infra).
2.3.1. MVG
The first vinylic amino acid bearing an enol ether functionality
to be characterized was 4E-methoxyvinylglycine 5 (MVG), isolated from Pseudomonas aeruginosa.34 and 35 Interestingly, this
vinyl ether serves as a substrate of methionine γ-lyase,15 and
both a substrate and an inhibitor of tryptophan synthase.36 & 12
In pioneering work, Rando showed that 5 inactivates porcine aspartate aminotransferase.37 & 38 Similar observations were made
with the rat enzyme.18 E-MVG has been reported to inhibit porphobilinogen synthase,39 as well as δ-aminolevulinic acid synthetase and dehydratase from rat tissue.40 As it turns out, the Zisomer of MVG, though apparently not naturally occurring, is
one of the most effective inhibitors of methionine adenosyltransferase.41 & 42 This is discussed in more detail in Section 4.
2.3.2. AVG
The E-isomer of 4-(2′-aminoethoxy)vinylglycine, AVG 6 can
be biosynthesized in Streptomyces.43 Like MVG, AVG bears
an oxygen at the γ-carbon, and so resembles methionine. However, unlike MVG, AVG has a more extended side chain, terminating is an ammonium group, that is positively charged at
physiological pH. This ammonium group is positionally juxta-

posed on the cysteine-derived ammonium group of l, L-cystathionine. Whereas Z-MVG serves as an apparent L-methionine
isostere in the methionine adenosyltransferase active site, unsurprisingly, AVG was found to inhibit cystathionine processing enzymes including cystathionine β-lyase,44 & 43 and human
recombinant cystathionine γ-lyase.45 AVG also inhibits cystalysin,46 the enzyme that catalyzes the β-elimination of cysteine to pyruvate, ammonia, and H2S.
Most importantly, the positively charged ammonium group
along the methionine-like side chain engenders AVG with a
structural similarity to SAM. Indeed, AVG is a well-known
inhibitor of 1-aminocyclopropane-1-carboxylate (ACC) synthase, the PLP enzyme that converts SAM into ACC. Since this
serves as a key step in plant ethylene biosynthesis, AVG has
seen wide application as a fruit ripening inhibitor. The ACC
synthase inhibitory behavior of AVG has been characterized
with the enzymes from both red tomato and apple.47, 48, & 49
2.3.3. Rhizobitoxine
The third and most structurally complex member of the enol
ether subfamily of the α-vinylic amino acids is rhizobitoxine
7. The backbone of this amino acid superimposes upon that
of AVG, but a second stereocenter is added precisely where
the second stereocenter in cystathionine is located. Only here,
a hydroxymethyl group is appended to this stereocenter, in
place of the cystathionine carboxylate group, and with the appropriate stereochemistry to mimic this amino acid.
Rhizobitoxine is produced by symbiotic bacteria, such as Rhizobium japonicum,50, 51, & 52 and also by the plant pathogen,
Pseudomonas andropogonis.53 Presumably, at least in part because of its close structural resemblance to cystathionine, rhi-
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zobitoxine inhibits cystathionine β-lyase, from both Salmonella typhimurium and spinach.50 & 54 Rhizobitoxine also decreases
hydrogenase biosynthesis in Bradyrhizobium japonicum,55 by
inhibiting depression of the hydrogenase gene. However, as this
effect is reversed by the addition of methionine, this may be a
downstream consequence of rhizobitoxine’s inhibition of methionine biosynthesis at the cystathionine β-lyase stage.
Probably the most important activity of rhizobitoxine resides
in its ability, analogous to AVG, to inhibit ACC synthase.56
This is one of the two important mechanisms by which symbiotic bacteria are known to inhibit ethylene biosynthesis in the
roots of their host legumes.57 The other is through the activity of bacterial SAM deaminase, which rather than inhibit the
conversion of SAM to ACC, simply siphons off SAM by oxidative deamination. As the plant hormone, ethylene, is known
to inhibit root nodulation, rhizobia have presumably evolved
these interesting mechanisms for ethylene biosynthesis inhibition to insure a favorable nodulation environment for their
survival. As there are agricultural biotechnological interests in
nitrogen fixation, rhizobitoxine and/or the rhizobitoxine biosynthetic machinery may have future applications here.
2.3.4. Other γ-substituted VG analogues
A naturally occurring phosphonate analogue of homoserine
phosphate, Z-2-amino-5-phosphono-3-pentenoic acid 9 (ZAPPA) is a constituent of the dipeptide rhizocticins,58 & 59 and
tripeptide plumbemycins.60 & 59 One might predict, that the free
amino acid, APPA is active against PLP enzymes that normally
take L-homoserine phosphate as a substrate. This includes cystathionine γ-synthase (synthesize cystathionine from cysteine
and homoserine phosphate) for which E-APPA is a tight-binding reversible inhibitor (see Section 4 for further discussion).61
Threonine synthase is a PLP enzyme that performs a β,γ-phosphate elimination/β-hydration sequence from L-homoserine
phosphate. The threonine synthase enzyme from E. coli is irreversibly inactivated by both the E- and Z-isomers of APPA.62
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of Streptomyces viridogenes.72 The function of these interesting α-vinylic amino acids remains to be elucidated (Fig. 5).

Figure 5. β,γ-Substituted vinylic amino acids.

3. Asymmetric synthesis
Owing to its interesting enzyme-inhibitory activity and its potential as a synthon,73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87,
88, 89, & 90 vinylglycine has attracted the attention of synthetic
chemists. Hence, a variety of asymmetric synthetic methodologies to access D- and L-vinylglycine are available in the current literature. A compilation of known stereocontrolled approaches for this important target is presented below.
3.1. Chiron-based entries into vinylglycine
Afzali-Ardakani and Rapoport reported the first synthesis of
vinylglycine from L-methionine.91 In this synthesis, controlled
oxidation to the sulfoxide, followed by pyrolysis under Kugelrohr conditions, allowed them to distill over the protected vinylglycine product as it forms. Deprotection produces L-vinylglycine in 99% enantiomeric excess (Scheme 1).

E-3,4-Dehydro-2-aminopimelic acid 8 has been isolated from
Aspenium unilaterale.63 & 64 Z-3,5-Hexadienoic acid 10 (butadienylglycine) is found in the defensive secretions of Doryphorina beetles,65 Platyphora kollari beetles,66 and in the fruiting
bodies of Clavulinopsis helvola.67 Amino acids 11 and 12 were
found as amino acid constituents of the dipeptide trypsin inhibitor, radiosumin A, biosynthesized by the cyanobacterium
Plectonema radiosum.68 & 69 The two differ only through Nacetylation at the 8-position in compound 12, and the unsaturation across the 5,6-carbons in compound 11. The very closely
related amino acids, 13 and 14, are the constituents of a similar
dipeptide trypsin inhibitor, later identified in the cyanobacterium Microcystis aeruginosa, and named radiosumin B.70
2.4. β,γ-Disubstituted
Densely functionalized vinylic amino acids 15 and 16, differing only in the oxidation state of the β-appendage, were isolated together from the mushroom Bankera fulgineoalba.71 The
novel chlorinated glutamate analogue, 17, is found in isolates

Scheme 1. Rapoport’s sulfoxide pyrolysis entry.

A photofragmentation approach, again starting from L-methionine has been developed by Griesbeck et al.92 & 93 Irradiation
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of the sulfoxide(s) 21a/b at 300 nm in acetonitrile gives methyl N-phthaloyL-L-vinylglycinate 24. This protocol encountered problems due to side reactions when substrate concentrations above 10 mM were used. This limitation was overcome
by photolyzing the ring-opened product of L-homoserine lactone with HBr or HCl (Scheme 2).

Scheme 4. Arylselenium introduction via the Grieco protocol.

Scheme 2. Griesbeck’s photofragmentation route from L-methionine.

Berkowitz et al. also developed a practical route to L-vinylglycine from homoserine lactone, in this case, via organoselenium
chemistry (Scheme 3).94 Thus, opening of N-Boc-protected Lhomoserine lactone 26 with phenylselenolate anion occurs exclusively at the softer γ-carbon, allowing for subsequent installation of the double bond via syn elimination of the selenoxide.
Scheme 5. Hanessian’s oxidative decarboxylation of L-glutamate.

group (Scheme 5).99 Townsend et al. later reported improvements in the procedure, based upon the use of benzyl and
benzhydryl esters to facilitate the purification (crystallization), deprotection, and assessment of enantiomeric purity.84
A complementary route from L-glutamate exploits the Barton
decarboxylation of N-hydroxyl-2-chalcogenopyridone esters
(Scheme 6).100 The photochemical decarboxylative rearrangement of ester 32 provides the γ-arylselenide 33 directly. This in-

Scheme 3. Berkowitz et al.’s use of phenylselenolate lactone-opening chemistry.

A route developed by Pellicciari et al.,95 likewise employs Lhomoserine as the chiron, and also avails itself of selenoxide elimination chemistry. In this route, however, rather than
use nucleophilic lactone opening for the introduction of selenium, a modified Mitsunobu protocol developed by Grieco96,
97, & 98 was exploited (Scheme 4).
There are two classic vinylglycine syntheses that employ Lglutamate as the chiron. Early on, Hanessian developed an elegant route based upon a Cu(II)/Pb(IV)-mediated oxidative
decarboxylation of the γ-carboxylate to introduce the vinyl

Scheme 6. Decarboxylative introduction of selenium via a Barton ester.
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termediate is primed for introduction of the α-vinyl group via oxidative pyrolysis of the pyridyl selenide. One obtains protected Lvinylglycine in acceptable yield and with uncompromised ee.
Diaz-de-Villegas et al.101 have achieved the synthesis of L-vinylglycine from D-glyceraldehyde. This synthesis utilizes stereochemical communication, wherein the original, chiral poolderived stereocenter is used to induce stereochemistry in an
adjacent center, and is then excised oxidatively in unveiling the
α-carboxyl group. A highly diastereoselective vinyl-Grignard
addition to N-benzyl-2,3-O-isopropylidene-D-glyceraldimine is
the hallmark of this synthesis (Scheme 7). Note that the diastereopreference observed is in accordance with the Felkin-Anh
model. However, for such cyclic systems, the authors suggest
that other transition state models might also be considered.102
also serves as a chiral pool precursor to L-vinylglycine, via methylenation protocols, though here extra care must
be taken to minimize racemization of the intermediate aldehyde. Thus, Lajoie et al.103 report that application of the Peterson olefination to a suitably protected L-serinal derivative leads
to L-vinylglycine in high ee (Scheme 8). Whereas attempts to
induce conversion of the intermediate β-hydroxysilane 40 to
the alkene with base failed, acidic conditions not only succeeded, but also permitted concomitant Cbz and OBO orthoester
deprotection. Note that other olefination methods examined
generally gave a significant degree of racemization. In a similar vein, Beaulieu et al.104 used methylenation of the Garner aldehyde to access vinylglycine, albeit in modest yields and ee.
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3.2. Enzymatic kinetic resolutions to VG
In a couple of instances, enzymatic kinetic resolution has been
applied to VG targets. Very early on, Helboe et al.105 subjected
(dl)-vinylglycine, obtained via a Strecker synthesis with acrolein, to fermentation with baker’s yeast. D-Vinylglycine was
obtained in 39% yield and 82% ee.
Later, Crout et al.106 described an interesting route to racemic
vinylglycine via Neber rearrangement of N-chloroimidate 41.
This was followed by a papain-mediated esterification in a biphasic system to give the individual antipodes (Scheme 9).
Two cycles were employed to obtain the remaining D-enantiomer. Precise ee determinations were not reported, but the specific rotations reported compared well with literature values.

L-Serine

Scheme 9. Neber rearrangement/papain-based kinetic resolution.

3.3. Chiral auxiliary-based approaches to VG

Scheme 7. Galvez’s Felkin-Anh-vinylation route from D-glyceraldehyde.

Schöllkopf107 demonstrated that his widely employed chiral
glycine enolate equivalent could be formally α-vinylated using a vinyl cation equivalent developed by Hudrlik108 (Scheme
10). During the reaction, the condensation of the lithiated bislactim ether 44 (derived from L-valine and glycine) with 2(tert-butyldimethylsilyl)acetaldehyde proceeded in good yield
and with excellent cyclic stereocontrol. Subsequent treatment
with HCl serves to effect β-elimination of the elements of
“HO-SiR3” and unravel the bis-lactim ether auxiliary, yielding
free D-vinylglycine of high enantiomeric purity.

Scheme 8. Lajoie’s Peterson olefination route from L-serine.

Scheme 10. Schöllkopf’s formal vinylation of his chiral glycine enolate.
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Duhamel et al. examined the possibility of inducing asymmetry from an external chiral acid source, upon enolate quenching. Specifically, the benzophenone imine-protected dehydrobutyrine derivative 46 was deprotonated with LDA to generate
an extended dienolate 47, that was then quenched at −70 °C
with (R,R)-O,O′-dipivaloyltartaric acid. This kinetic quench
produced a 42:58 ratio of α- to γ-protonation, with the former
(deconjugation) product showing modest facial selectivity in
favor of the D-antipode of vinylglycine (Scheme 11).

cess leads to the formation of (S)-2-phthalimido-3-buten-1-ol 50,
which is then transformed to vinylglycinol in two steps.
Recently, in the context of an ISES (in situ enzymatic screening) approach to catalyst discovery,112 our group reported the
first examples of asymmetric Ni(0)-mediated allylic amination
chemistry.113 & 114 Here an N-protected-4-vinyloxazolin-2-one
intermediate was generated via an enantioselective, intramolecular allylic amination with a Ni(0)-BIPHEP catalyst system
(Scheme 13). This was then transformed to L-vinylglycine.

Scheme 11. Duhamel’s chiral acid dienolate protonation approach.

Scheme 13. Berkowitz et al.’s Ni(0)-mediated asymmetric allylic amination
route.

3.4. Catalytic asymmetric syntheses of vinylglycine

3.5. Methoxyvinylglycine (MVG)

al.109, 110, & 111

Trost et
have developed an elegant DYKAT (dynamic kinetic asymmetric transformation) approach to L-vinylglycinol from racemic butadiene monoepoxide (Scheme 12). The
approach hinges on a Pd(0)-mediated allylic amination reaction,
with ligand 49 serving to provide the chiral scaffold about Pd.
Phthalimide is used as N-nucleophile and no exogenous base is
needed, as relief of ring strain is used to form a formally chargeseparated π-allyl-Pd intermediate, bearing a transient alkoxy
leaving group. Presumably, this alkoxide is well suited to deprotonate the phthalimide nucleophile and deliver it to the appended π-allyl acceptor. This highly regio- and stereoselective pro-

An N-acylase mediated resolution of the Z- and E-isomers of
MVG has been reported by Keith et al. (Route A, Scheme 14).115
Alks116 introduced the following two modifications: (i) stereose-

Scheme 12. Trost’s DYKAT asymmetric allylic amination route.

Scheme 14. Introducing the enol ether into E- and Z-MVG.
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lective synthesis of N-Ac-(dl)-E-MVG methyl ester; (ii) thermal
isomerization of the E- to Z-methyl ester (Route B, Scheme 14).
Acylase resolves each geometric isomer of MVG, by selectively deacetylating the L-amide115 (Scheme 15).
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lithiated chiral bis-lactim ether 44, sets the α-stereochemistry in both approaches. Here, the use of acrolein results
in an allylic center, which can then be coerced to undergo Pd(II)-mediated allylic transposition, albeit in modest
yield, to 64. Subsequent Arbuzov chemistry installs the terminal phosphonate (Scheme 17).

Scheme 15. Enzymatic resolution of E- and Z-MVG.

3.6. Rhizobitoxine
A concise synthesis of L-rhizobitoxine has been reported by Keith
et al.117 (Scheme 16). The key transformation is a palladium(II)mediated trans-vinyl etherification between N-Cbz-O-benzyl-Dserinol and N-Cbz-L-MVG benzyl ester (E:Z 3:2).

Scheme 17. Kirihata’s approach to E-APPA.

4. Mechanism
4.1. Vinylic amino acids as conformationally constrained
amino acid analogues?
As was mentioned earlier, Z-MVG, the geometric isomer of
the natural product, inhibits methionine adensyl transferase,
the enzyme responsible for the synthesis of SAM [(S)-adenosylmethionine] from ATP and L-methionine. The crystal
structure of this enzyme in complex with Z-MVG reveals the
L-methionine binding site.41 & 42 This may be an example of
an α-vinylic amino acid that serves as a good conformationally constrained analogue of the saturated, and hence, inherently more flexible, natural substrate.

Scheme 16. Keith’s route to rhizobitoxine.

3.7. 2-Amino-5-phosphono-4-pentenoic acid (APPA)
Kirihata has reported an asymmetric synthesis of E-APPA
that strategically resembles Schöllkopf’s vinylglcyine synthesis (Scheme 10), in that reaction of an aldehyde with the

Similarly, perhaps E-APPA, also the geometric isomer of the natural product, acts as a reversible, tightly bound analogue of homoserine phosphate in the active site of cystathionine γ-synthase
(CGS).61 In this case as well, the X-ray crystal structure of the
E–I complex, identified the binding pocket of the phosphate side
chain of the natural substrate. This suggests this vinylic amino
acid with its E double bond configuration mimics L-homoserine
phosphate “frozen” in an extended conformation, that is especially productive for binding. The X-ray structure reveals that EAPPA interacts with both the α-carboxylate and side chain phosphate binding pockets of CGS, in support of this view.
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In the sections to follow, we focus on inhibition mechanisms
that appear to require enzymatic chemistry beyond the simple
initial transimination reaction that is the canonical first step in
the binding of an amine substrate or substrate analogue to a
PLP enzyme. In this sense, the mechanisms that follow highlight the possibility for mechanism-based or enzyme-activated
inhibition in this class of α-vinylic amino acids.
4.2. Mechanism A—vinylogous imidate formation
The first mechanism that we wish to consider is likely favorable for the subclass of α-vinylic amino acids that features a
heteroatom directly attached to the γ-carbon. This is the case
for MVG, AVG, and rhizobitoxine (Fig. 4), for which the heteroatom is oxygen (i.e., enol ethers), though the same principle
could apply to other heteroatoms. Although Rando first carried
out important mechanistic studies on the inhibition of aspartate
aminotransferase by MVG many years ago, crystallographic information on the bound states of members of this vinylic
amino acid class has only appeared much more recently.
As illustrated in Scheme 18, transimination from the resting state of the PLP enzyme would produce the external aldimine in which the α-vinylic functionality remains isolated
from the π-system of the cofactor. As mentioned in the out-

set of this Report, the first mechanistic step for a PLP dependent transaminase, racemase, or eliminase is α-deprotonation. This produces a quinonoid intermediate in which the
vinyl group is now fully conjugated with the PLP system.
However, heteroatoms with donating lone pairs oppose one
another at the ends of this system. Should protonation at C4′ ensue, this would have the effect of removing the N-1lone pair from the system, and this generates a vinylogous
imidate. Such a ketimine is expected to benefit from the excellent alkoxy electron donor/iminium electron acceptor juxtaposition at the ends of this five atom π-system. In other
words, the π-delocalization energy inherent in the enol ether
functionality of the inhibitor would have been significantly
enhanced through an enzyme-mediated azaallylic isomerization, leading to this stable bound cofactor adduct.
In fact, three X-ray crystal structures are available for AVG
bound in PLP enzyme active sites (Fig. 6): apple ACC synthase (PDB ID: 1M7Y; 1.6 Å),49 cystalysin (PDB ID: 1C7O;
2.5 Å),46 and cystathionine β-lyase (PDB ID: 1CL2; 2.2 Å).44
It should be noted that these enzymes are all eliminases, catalyzing the α,γ-elimination of SAM to ACC, the α,β-elimination of cysteine to pyruvate (eventually) and the α,β-elimination of cystathionine to cysteine, respectively. So, all
inherently α-deprotonate their natural substrates.

Scheme 18. Mechanism A: vinylogous imidate formation from γ-alkoxy-α-vinyl amino acids via PLP enzyme-catalyzed azallylic isomerization.

Figure 6. Cofactor-AVG adducts bound in three PLP enzyme active sites (PDB codes: 1M7Y, 1C7O, and 1CL2, respectively).
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The ACC synthase structure is the highest resolution of the
three and also provides the best evidence for such a bound vinylogous imidate. The dihedral angles across the Cγ–Cβ and Cβ–
Cα bonds are modeled at 177° and −146°, respectively, consistent with such conjugation. Furthermore, the C4′–N–Cα–Cβ and
C4′–N–Cα–carboxylate dihedrals are at 7° and −175°, respectively, consistent with azallylic isomerization having occurred
in the ACC synthase active site. Deviation from planarity increases across Cβ–Cα as one moves from this structure to the
CBL structure, but near planarity is retained across Cγ–Cβ. The
cystalysin structure provides little evidence for such conjugation, but is also the lowest resolution of the three. Furthermore,
the uncertainty inherent in E–I X-ray structures of this sort does
not allow us to assign the double bond loci with certainty.
Nonetheless, the notion that γ-alkoxy-α-vinylic amino acids have a preference to form stabilized vinylogous imidate
complexes with PLP would appear to be a chemically reasonably postulate, worthy of further scrutiny in investigations of this amino acid subclass. Interestingly, in his early
work with MVG, Rando observed a pronounced tendency of
that amino acid to undergo azaallylic isomerization, even in
Snell-type model reactions with PLP and Al3+,38 consistent
with the notion of a thermodynamic driving force toward vinylogous imidate formation in these adducts.
4.3. Mechanism B—Michael addition
Vinylglycine, the parent member of the α-vinyl amino acid
family was isolated from a mushroom source in 1974.8 In
the same year, Rando reported on its irreversible inactivation of a PLP enzyme, namely aspartate aminotransferase.17
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As was discussed earlier (Section 2.1), vinylglycine inactivates a number of PLP enzymes, most of which are transaminases. Yet only in the past year has the nature of the covalent
adduct formed between vinylglycine and one of its target enzymes lent itself to crystallographic characterization. This feat
was accomplished with the enzyme ACC synthase.24 This enzyme normally engages its natural substrate, SAM in PLP aldimine linkage, followed by α-deprotonation. An unusual expulsion of the γ-leaving group, methylthioadenosine (MTA),
is the normal next mechanistic step, leading to the formation
of the strained cyclopropane ring of ACC.
As is discussed in greater detail below, L-vinylglycine is
both an inhibitor and an abnormal (β,γ-elimination) product
of this enzyme. A possible mechanism for the inactivation
of ACC synthase with L-vinylglycine is depicted in Scheme
19. The normal first step, α-deprotonation is followed by C4′-protonation, as in Mechanism A, leading to an α,β-unsaturated iminium ion. This Michael acceptor is then captured
by an active site nucleophile. The active site lysine is always
a candidate for this role, as it is displaced in the initial transimination step. This lysine residue then presumably remains
in the vicinity of the resulting E–S or E–I adduct and of the
complexes mechanistically derived therefrom.
The 2005 Grütter/Kirsch crystal structure of ACC synthase inactivated with L-vinylglycine is depicted in Figure 724 and reveals that, indeed, the active site lysine has formed a covalent
bond with the γ-carbon of the inhibitor, as predicted. The observation of the three dimensional structure of this adduct cements perhaps the most widely accepted mechanism for actuation of the α-vinylic trigger. It also serves to rule out an
alternative Michael addition pathway, whereby α-deproton-

Scheme 19. Mechanism B: inactivation of ACC synthase by L-vinylglycine via enzyme-catalyzed azaallyllic isomerization-Michael addition.
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Figure 7. Evidence of Mechanism B for L-vinylglycine with ACC synthase (PDB 1YNU) and for vigabatrin with GABA transaminase (PDB 1YHW).

ation would be followed by γ-protonation, leading to an electrophilic β-, rather than γ-carbon.
Finally, the α-vinylic trigger found in the class of amino acids
being reviewed here surely served as the inspiration for development of vigabatrin (γ-vinyl-GABA), as a mechanism-based
inactivator of GABA transaminase. Vigabatrin was developed
by the Marion Merrell Dow group into an anti-epileptic drug of
widespread use, particularly in Europe.118 It is probably fair to
say that Vigabatrin was designed to act by a Michael addition
mechanism analogous to Mechanism B (Scheme 19). Indeed,
elegant mechanistic studies by the groups of Silverman119 and
John120 pointed to such a mechanism as the primary one through
which the drug inactivated its target enzyme, GABA transaminase. Pleasingly, the X-ray crystal structure appeared in 2004,121
and served to validate this mechanism, again with the active site
lysine serving as the Michael nucleophile (Fig. 7).
4.4. SMM: A natural “Pro-Form” of a vinylic amino acid?
The enzyme ACC synthase not only ended up serving as the
showcase for the long-suspected Michael addition inactivation
pathway of vinylglycine, it has also brought to light a novel
mechanism by which Nature may biosynthesize vinylic amino
acid progenitors. Namely, through a series of elegant studies
from Kirsch et al., it has now been established that even subtle changes in the vicinity of the γ-leaving group of the SAM
substrate for ACC synthase can lead to profound changes in
mechanistic partitioning in the active site. These findings are
illustrated schematically in Scheme 20.
Kirsch first studied the effect of the often ignored sulfur stereocenter in SAM on ACC processing. Natural SAM has the SS
stereochemistry, and undergoes errant β,γ-elimination to vinylglycine only once for every 60 α,γ-eliminations to ACC.27 On
the other hand, inversion of this sulfonium stereocenter alone,
retaining the important L-methionine center, results in a partition reversal. β,γ-Elimination now predominates by a 2.5:1 ratio over the usual α,γ-elimination.26 This is really a remark-

Scheme 20. Fate of SAM and analogues in the ACC synthase active site.

able observation, especially when one considers that these two
substrates not only share the same α-stereochemistry, but have
chemically exactly the same leaving group, MTA.
Perhaps led by this result, Kirsch et al. then decided to examine the behavior of L-(S)-methylmethionine (SMM), a ubiquitous component of the tissues of flowering plants; SMM undergoes no α,γ-elimination whatsoever with ACC synthase.
Instead, a small amount of transamination to the ketone is observed. Otherwise, one sees almost exclusive conversion of
SMM to vinylglyine in this active site.
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Furthermore, there is 15-fold greater probability for SMM-derived “vinylglycine” to inactivate, when compared with SAMderived “vinylglycine.” This probably reflects a greater percentage of enamine tautomer (i.e., γ-protonation) in the SAM
case, leading to more α-ketobutyrate product, as opposed to C4′-protonation, which would lead to the inactivating Michael
acceptor. These studies raise the intriguing possibility that LSMM is a natural, masked progenitor of L-vinylglycine, itself
a masked enzyme inactivator. Why two layers of unmasking?
One possibility lies in the relatively broad spectrum PLP-enzyme inactivation profile of vinylglycine itself. Perhaps Nature has biosynthesized SMM as a way of targeting specific
formation of vinylglycine to the ACC active site.
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